New pill could help control high cholesterol – study underway

NCT ID NCT06834932

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called AZD0780 in 432 adults with high LDL cholesterol (dyslipidaemia). Participants take the drug or a placebo daily for up to 52 weeks to see if it safely lowers cholesterol. The goal is to manage the condition, not cure it, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDAEMIA

Contacts and locations

Locations

Research Site

Baotou, 14010, China
Research Site

Beijing, 100029, China
Research Site

Beijing, 100050, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130021, China
Research Site

Changchun, 130033, China
Research Site

Changde, 415000, China
Research Site

Changsha, 410015, China
Research Site

Changzhou, 272100, China
Research Site

Chengdu, 610000, China
Research Site

Chongqing, 402260, China
Research Site

Daqing, 163000, China
Research Site

Deyang, 618000, China
Research Site

Guangzhou, 510100, China
Research Site

Guangzhou, 510220, China
Research Site

Hengyang, 421001, China
Research Site

Heze, 274099, China
Research Site

Linhai, 317000, China
Research Site

Luoyang, 471000, China
Research Site

Nanchang, 330009, China
Research Site

Nanchong, 637900, China
Research Site

Nanjing, 210009, China
Research Site

Pingxiang, 337055, China
Research Site

Qiqihar, 161000, China
Research Site

Sanya, 572000, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200120, China
Research Site

Shanghai, 310000, China
Research Site

Shenyang, 110004, China
Research Site

Shenyang, 110016, China
Research Site

Siping, 136000, China
Research Site

Taiyuan, 030024, China
Research Site

Tianjin, 300457, China
Research Site

Wuhan, 430010, China
Research Site

Wuhan, 430030, China
Research Site

Wuhan, 430060, China
Research Site

Xi'an, 710068, China
Research Site

Xianyang, 750004, China
Research Site

Yinchuan, 750004, China
Research Site

Zigong, 643021, China
Research Site

Hong Kong, 999077, Hong Kong
Research Site

Hong Kong, Hong Kong
Research Site

Shatin, 00000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.